As of 2024-12-14, the Relative Valuation of Anavex Life Sciences Corp (AVXL) is (8.77) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.46 USD, the upside of Anavex Life Sciences Corp based on Relative Valuation is -203.6%.
The range of the Relative Valuation is (5.46) - (9.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 24.1x | 17.3x |
| Forward P/E multiples | 11.1x - 18.9x | 18.5x |
| Fair Price | (5.46) - (9.24) | (8.77) |
| Upside | -164.5% - -209.2% | -203.6% |
| Date | P/E |
| 2024-11-21 | -18.42 |
| 2024-11-20 | -17.31 |
| 2024-11-19 | -16.83 |
| 2024-11-18 | -15.21 |
| 2024-11-15 | -15.20 |
| 2024-11-14 | -16.40 |
| 2024-11-13 | -18.15 |
| 2024-11-12 | -18.42 |
| 2024-11-11 | -18.68 |
| 2024-11-08 | -18.87 |
| 2024-11-07 | -15.59 |
| 2024-11-06 | -15.91 |
| 2024-11-05 | -15.72 |
| 2024-11-04 | -14.91 |
| 2024-11-01 | -13.96 |
| 2024-10-31 | -13.52 |
| 2024-10-30 | -11.66 |
| 2024-10-29 | -11.67 |
| 2024-10-28 | -11.80 |
| 2024-10-25 | -10.70 |
| 2024-10-24 | -10.88 |
| 2024-10-23 | -11.01 |
| 2024-10-22 | -11.52 |
| 2024-10-21 | -11.13 |
| 2024-10-18 | -11.54 |
| 2024-10-17 | -11.24 |
| 2024-10-16 | -11.28 |
| 2024-10-15 | -11.01 |
| 2024-10-14 | -11.05 |
| 2024-10-11 | -10.99 |
| 2024-10-10 | -10.43 |
| 2024-10-09 | -10.48 |
| 2024-10-08 | -10.70 |
| 2024-10-07 | -10.97 |
| 2024-10-04 | -11.42 |
| 2024-10-03 | -11.44 |
| 2024-10-02 | -11.55 |
| 2024-10-01 | -11.11 |
| 2024-09-30 | -11.60 |
| 2024-09-27 | -11.60 |
| 2024-09-26 | -11.58 |
| 2024-09-25 | -11.13 |
| 2024-09-24 | -11.35 |
| 2024-09-23 | -11.21 |
| 2024-09-20 | -11.52 |
| 2024-09-19 | -11.76 |
| 2024-09-18 | -11.23 |
| 2024-09-17 | -11.15 |
| 2024-09-16 | -11.64 |
| 2024-09-13 | -10.84 |